4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.

Emiliano RoselliJustin C BoucherGongbo LiHiroshi KotaniKristen SpitlerKayla ReidEstelle V CervantesYannick BulliardNhan TuSae Bom LeeBin YuFrederick L LockeMarco L Davila

Published in: Journal for immunotherapy of cancer (2022)

These results demonstrate that co-stimulation combining 4-1BB with an optimized form of CD28 is a valid approach to optimize CAR T cell function. Cells with both mono-specific and bi-specific versions of this design showed enhanced in vitro and in vivo features such as expansion, persistence and resistance to exhaustion. Our observations validate the approach and justify clinical studies to test the efficacy and safety of this CAR in patients.

Keyphrases

end stage renal disease
endothelial cells
growth factor
newly diagnosed
induced apoptosis
chronic kidney disease
prognostic factors
cell death
signaling pathway
recombinant human